Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11347411 | 0.85 | DPP4 (0.47) | PAX8DPP4DPP8DPP7 | |
| SCHEMBL11347414 | 0.85 | DPP4 (0.47) | PAX8DPP4DPP8DPP7 | |
| SCHEMBL1627439 | 0.82 | DPP4 (0.42) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL1796260 | 0.82 | DPP4 (0.42) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL8509053 | 0.82 | DPP4 (0.42) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL28057635 | 0.82 | SLC7A5 (0.42) | — | |
| SCHEMBL1627442 | 0.81 | DPP4 (0.41) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL9797925 | 0.81 | DPP7 (0.47) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL9797920 | 0.81 | DPP7 (0.47) | PAX8DPP4DPP8DPP7CTRB1 | |
| SCHEMBL9177741 | 0.78 | GABRP (0.47) | DPP4DPP8DPP7NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916800-B2 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | PFIZER INC (US) | 2005-07-12 | — | — | US | disclosed |
| US-6858598-B1 | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | G. D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |